Para IV notice: Endo International gets Paragraph IV notification on Vasostrict
Posted on19 Apr 2018
Comments0
Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated April... Read More
AstraZeneca, Daiichi Sankyo to introduce Nexium 10 & 20 mg granules for suspension, Sachet, in Japan
AstraZeneca K.K. and Daiichi Sankyo Company Limited announced the launch of proton pump inhibitor Nexium 10 mg and 20 mg granules for... Read More
Glenmark and Helsinn Group’s exclusive licensing deal for launch of Akynzeo in India and Nepal
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, and Helsinn Group (“Helsinn”), a Swiss pharmaceutical group focused on building quality cancer... Read More
Natco launched a generic version of Teriflunomide tablets for the treatment of relapsing and remitting forms of multiple sclerosis in India
Natco Pharma launched a generic version of Teriflunomide for the treatment of relapsing and remitting forms of multiple sclerosis (RRMS), under its... Read More
Brand Positioning: GSK Consumer Healthcare Ltd launches Horlicks Protein+
Posted on19 Mar 2018
Comments0
GSK Consumer Healthcare Ltd, the maker of Horlicks, is making another attempt to diversify. The company is set to launch Horlicks Protein+,... Read More
New Launch: Hetero launches – Tafero-EM – FDC combo of ‘emtricitabine & tenofovir alafenamide’ in India
Hetero, one of India’s leading generic pharmaceutical companies and world’s largest producer of anti-retroviral drugs, announced the launch of the first generic... Read More
Cipla – Roche Deal – Cipla will promote and distribute Roche’s tocilizumab and Syndyma in India
Cipla Ltd and Roche Pharma India has entered an agreement under which Cipla will promote and distribute tocilizumab and Syndyma, the 2nd... Read More
AstraZeneca launches once-daily Xigduo XR tablets for comprehensive management of type 2 diabetes in India
AstraZeneca Pharma India Limited (AstraZeneca India) has announced the launch of its innovative anti-diabetic combination once-daily therapy Xigduo XR for treatment of... Read More
What is the well-known mark? How it differs from regular trademark?
A famous or well-known mark is a trademark that, in view of its widespread reputation or recognition, may enjoy broader protection than... Read More
Pharma Strategy Lookouts: Dizal Pharmaceutical, JV of AstraZeneca in China
Posted on28 Nov 2017
TagsAstraZenca, Dapagliflozin, Dizal Pharmaceutical, Farxiga, osimertinib, SGLT-2 inhibitor, Tagrisso, Type 2 Diabetes
Comments0
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China... Read More